Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus placebo in patients with type 2 diabetes and moderate renal insufficiency

Next Previous
Search
Trial Profile

A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus placebo in patients with type 2 diabetes and moderate renal insufficiency

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Diabetic nephropathies; Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Sponsors Novartis

    • Most Recent Events

    • 12 Jun 2012 Long-term tolerability results from the 28-week extension phase of the study presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
    • 01 Oct 2011 Results published in the Diabetes, Obesity and Metabolism.
    • 16 Sep 2011 24 week results presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top